AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high ...

This investigational treatment was generally well tolerated with no serious adverse events; fewer adverse events related to non-motor symptoms were reported in the solengepras arm Pivotal Phase 3 ...

MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a clinical-stage biopharmaceutical ... “Beyond Parkinson’s disease, we have additional Phase 2 studies planned for VENT-02, including a Phase ...

One thing that will require a closer look is the depletions in pathways involved in the synthesis of acetate and butyrate [2 SCFAs] in both Parkinson’s and inflammatory bowel disease.